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Abstract
Crohn's disease is a relapsing-remitting disorder of the
gastrointestinal tract caused by a mixture of genetic and environmental factors. Pharmacologic treatment of Crohn's
disease is patient-specific, and regimens vary widely between individuals. Drug regimens are typically based on
5-aminosalicylate therapy and may include a combination of
steroids, histamine 2 receptor antagonists, proton pump inhibitors, immunomodulators, antibiotics, biologic agents and
other medications aimed at symptom relief. A new medication, vedolizumab, is currently in phase III clinical trials
awaiting U.S. Food and Drug Administration (FDA) approval
for use in Crohn's disease. Vedolizumab is an alpha-integrin
inhibitor, which is anticipated to have a better safety profile
than Tysabri® ( natalizumab ), an alpha-integrin inhibitor
already approved for treatment of Crohn's disease. Pharmacists have an opportunity to educate Crohn's disease patients
about nonpharmacologic management including counseling
on diet, exercise, stress-relief therapy and use of multivitamins as well as the importance of regular colonoscopies and
visits to a primary care practitioner. Pharmacists can also
educate patients and practitioners about alternative therapies including probiotics, fecal microbiota transplantation
and fish oils which may help manage the disease.

Introduction
Crohn's disease is an inflammatory bowel disease (IBD),
which can negatively affect the lives of many patients. While
there are both pharmacologic and nonpharmacologic steps
all patients can take to suppress the disease and its complications, treatment is highly individualized. Many patients will
often not respond to initial therapy or may lose responsiveness over time. The need for new medications to combat
Crohn's disease is highly recognized. Vedolizumab has completed phase III clinical trials and is awaiting FDA approval.
Its safety and efficacy in these trials are encouraging for potential use in Crohn's disease patients. Pharmacists can play
a large role in the management of these patients, as they will
be instrumental in monitoring complex drug therapies, ensuring appropriate laboratory testing, and educating patients
on diet, other nonpharmacologic treatments, and new investigational therapies. Pharmacists have the opportunity to
make a difference in improving the quality of life of Crohn's
disease patients in multiple settings, which include community, institutional, specialty pharmacy and primary care practice.
Background of Disease and Traditional Therapy
Crohn's disease is an increasingly prevalent idiopathic form
of IBD. Since it affects all ages and ethnicities, as well as both
men and women, Crohn's disease plays a significant role in
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the lives of approximately 6 million Americans.1 The chronic,
relapsing autoimmune inflammatory nature of this disease
typically presents as a discontinuation of the mucosa of the
gastrointestinal tract (GIT) and may result in complications
such as strictures, fistulas, lesions, obstructions or abscesses.
Lesions of the intestine are oftentimes irreversible. While the
mucosa of the entire GIT from the mouth to the anus can be
affected, the majority of cases are located in the terminal ileum and colon. Clinical implications include diarrhea or constipation, fever, abdominal pain, passage of mucus and blood
in the stool, signs of bowel obstruction, mouth sores and
clubbing of the fingernails,2,3 Diarrhea, as demonstrated by
an increase in frequency and decrease in consistency of stool,
is the most common clinical implication. Abdominal pain,
another common symptom, is typically seen in the right
lower quadrant and is exacerbated by eating.3 As a result of
this exacerbation with food, weight loss is a frequent occurrence in Crohn's disease.4
Crohn's disease is not a reportable condition in the United
States, which limits the ability to determine which populations are at highest risk. Data is also skewed by the difficulty
in differentiating Crohn's disease from a similar form of IBD
known as ulcerative colitis. Researchers have conducted multiple studies to determine the populations that have the highest incidence of Crohn's disease. Crohn's disease may occur
at any age, but most cases are diagnosed in early adulthood
with a large peak in adults 20 to 30 years old. A second peak
of incidence occurs in adults 50 to 60 years old.1.s About 25
percent of IBO diagnoses occur during childhood and, unfortunately, pediatric patients generally present with a more
severe form.s Pediatric cases of Crohn's disease occur more
often in boys than girls, but in adults more cases occur in
women than men. Data indicate more cases of Crohn's disease in the Northeast and Midwest regions of the United
States when compared to the Southern and Western regions.1 Historically, Crohn's disease is most common in Caucasians, with a genetic-based increase in prevalence among
individuals of Eastern European (Ashkenazi) Jewish descent.6 However, recent studies have shown an increase in
the rate of African-Americans presenting with Crohn's disease, and the rate of Crohn's-induced hospitalizations of African-Americans is now similar to Caucasians. Incidence in
Asian-Americans and Hispanic-Americans is significantly
lower compared to Caucasians and African-Americans.7
The exact cause of Crohn's disease is unknown, but the disease seems to be influenced by both genetics and environmental factors. Genome-wide association studies have shown
genetic variance to be the major contributor to about 23 percent of cases. These genetic variants have been shown to alter the regulation and efficiency of key molecular pathways
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in the body such as microbial defense, innate immune responses, autophagy, reactive oxygen species generation, and
lymphocyte differentiation.s Due to altered regulation, the
GIT is more prone to chronic injury and infection. Although
microorganisms such as Escherichia coli, Salmonella spp. and
Campylobacter spp. have been hypothesized to trigger the
onset of Crohn's disease, researchers have not been able to
pinpoint one specific microorganism as the causative agent.9
These harmful microorganisms can adhere to epithelial cells
of the intestine, replicate and stimulate an immune response,
which induces epithelial cell injury, causing inflammation
and discontinuation of the intestinal mucosa. Crohn's disease
patients are also commonly postulated to have a "leaky gut"
in which intestinal permeability is increased, resulting in
intestinal substances leaking out into the bloodstream. Moreover, most Crohn's disease patients have altered bowel flora,
which leaves the GIT unable to defend against the activity of
harmful microorganisms.3,s
Many factors contribute to an increase in harmful microorganisms in the intestinal mucosa. For example, the consumption of refined sugars and preservatives present in many
foods in the United States and other industrialized areas favor growth of detrimental bacteria in the intestine. As a result, diet can be a key component in the management of
Crohn's disease. Children growing up in areas with poor sanitation are exposed to an increased repertoire of pathogens
and infections, and thus, develop a more robust immune system. Therefore, these children may be protected against
agents which may induce Crohn's disease, resulting in lower
prevalence in children in areas of poor hygiene compared to
children who grow up with increased sanitation and less
pathogen exposure in industrialized areas. This idea is
known as the hygiene hypothesis and is theorized as a contributor to the development of IBD.10 Drug-induced Crohn's
disease is also possible. Chronic use of antibiotics can kill
protective bacteria in the intestine leaving the epithelial cells
more prone to injury by harmful microorganisms. Other risk
factors for developing Crohn's disease include cigarette
smoking and use of oral contraceptives.7
Currently, no definitive diagnostic test exists for Crohn's disease. Analysis of symptoms and clinical laboratory values as
well as endoscopic, histologic, and radiologic examination
criteria lead to confirmation of the disease.2,4 There is no gold
standard when it comes to treating Crohn's disease. There
are several different treatment guidelines available, including those from the American Academy of Family Physicians
(AAFP), the American College of Gastroenterology (ACG), and
the American Gastroenterological Association (AGA). However, the guidelines do not agree on a strong first-line
recommendation. Therefore, optimal first-line therapy is patient-specific and dependent on the location, severity and
any complications of the disease that are present. The two
primary goals of therapy are to treat acute flare-ups of symptoms and maintain remission. Other goals of therapy are limiting exposure to corticosteroids, minimizing adverse effects
of therapy, decreasing hospitalizations and improving patients' quality of life.
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Five classes of drugs affecting the small and large intestine
are typically utilized for Crohn's disease: 5-aminosalicylates,
immunomodulators, antibiotics, corticosteroids and biologics. For mild to moderate disease, 5-aminosalicylates such as
mesalamine, sulfasalazine, olsalazine and balsalazide are
most commonly used as first-line therapy to achieve remission. Topical mesalamine in the form of suppositories or enemas can be effective in treating distal Crohn's disease and
maintaining remission in mild to moderate patients. Immunomodulators such as azathioprine, mercaptopurine (6-MP),
and methotrexate (MTX) are useful in maintaining remission
when 5-aminosalicylates fail, in steroid-dependent disease
and in fistulizing disease. The use of the immunomodulator
cyclosporine is limited to cases of severe disease in which
other treatments have failed, due to its risk of serious side
effects. It is typically administered intravenously as a last
ditch effort to a hospitalized patient in an effort to prevent or
delay surgery. Antibiotics, including ciprofloxacin and metronidazole, can be used to treat fistulizing disease and flareups, while also playing a role in achieving remission in mild
to moderate disease when 5-aminosalicylates are not sufficient. Corticosteroids such as prednisone can be used to treat
acute flares and to induce remission in moderate to severe
disease, but should never be used long-term to maintain remission since it has a high incidence of serious side effects
including infection, osteoporosis, adrenal insufficiency, glaucoma, muscle wasting, fat redistribution and hypertension.
Corticosteroids should be tapered down slowly and as early
as possible in order to avoid these serious complications.
Biologics are typically reserved for fistulizing disease or severe disease refractory to other medication classes. Biologics
are commonly used as an alternative to immunomodulators
or occasionally in combination with immunomodulators,
although combination of these two classes is highly debated.11 Biologics include tumor necrosis factor alpha (TNFa) inhibitors adalimumab, infliximab, and certolizumab pegol, as well as the alpha-4 integrin inhibitor, natalizumab.
New Drug Therapy: Vedolizumab
Patients with moderate to severe Crohn's disease have often
tried and failed many medications including TNF-a inhibitors
such as adalimumab, infliximab and certolizumab pegol.
There is an unmet need for new therapies to treat patients
with severe disease. A new class of medications, known as
alpha-4 integrin inhibitors, has been developed for this purpose. This class includes the medication natalizumab
(Tysabri®), which is FDA approved for Crohn's disease. Integrin inhibitors act to prevent leukocyte extravasation
(crossing the endothelium of blood vessels) into the mucosa
of the GIT, which decreases the inflammatory response in
patients who have an upregulated, dysfunctional immune
system. 1 2 Extravasation of leukocytes involves the coordinated efforts of leukocytes and vascular endothelial cells.
lntegrins on the surfaces of leukocytes bind to receptors on
endothelial cells and activate intracellular signaling. The extravasation process involves multiple steps including tethering, rolling, activation, adhesion, extravasation and migration
as the leukocytes enter the GIT.12,n In Crohn's disease, it is
the T-cells expressing a4j37 integrin, which exclusively bind
to endothelium in the GIT and lymphoid tissue.12 The a4j37
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integrin binds to mucosa! addressin-cell adhesion molecule-1
(MAdCAM-1), which is a receptor only expressed on the vasculature of the GIT.12.14 MAdCAM-1 increases T-cell deposition in the GIT and is a major contributor to inflammation in
this region. Natalizumab was developed as a monoclonal antibody, which binds to the a4 integrin monomer, resulting in
binding both a4 integrin heterodimers on T cells, a4~7 and
a4~1, to block their respective attachments to the vascular
cell adhesion molecule-1 (VCAM-1) and MAdCAM-1. Binding
to a4~7 and a4~1 prevents integrin association with the
endothelial receptors and reduces extravasation of inflammatory cells. Natalizumab has been used successfully for
treatment in Crohn's disease, ulcerative colitis and multiple
sclerosis. 12 While it has displayed efficacy in multiple diseases, natalizumab has a major drawback of causing a serious and often fatal disease known as progressive multifocal
leukoencephalopathy (PML) caused by the John Cunningham
(JC) virus.12 Natalizumab was withdrawn from the market by
the FDA and reintroduced in 2006 with a specialized Risk
Evaluation and Mitigation Strategy (REMS) safety prescribing program. 12 The reason for this effect with natalizumab is
prevention of a4~1 integrin from binding to VCAM-1, which
is thought to negatively affect immunity in the central nervous system and increase the risk for development of PML.
Vedolizumab, a humanized version of a mouse antibody, selectively binds the a4~7 integrin.12,13 Vedolizumab is a
smaller molecule than natalizumab allowing it to selectively
target GIT integrins. Also, vedolizumab does not affect binding to VCAM-1 and has not yet been associated with development of PML.12,14 Like natalizumab, vedolizumab is administered intravenously. Vedolizumab has completed phase Ill
clinical trials and is awaiting FDA approval to be brought to
market. 12
A phase lII randomized, parallel-group, placebo-controlled,
double-blinded study conducted from December 2008 to
May 2012 evaluated the safety and efficacy of vedolizumab
as induction and maintenance therapy for Crohn's disease.
Inclusion criteria included patients 18 to 80 years old with at
least a three month history of Crohn's disease with a Crohn's
Disease Activity Index (CDAI) of 220 to 450 (CDAI scores
range from 0 to 600 with higher scores pointing to greater
disease activity). Patients also had to have other gastrointestinal markers of certain severity including: C-reactive protein, colonoscopy findings or fecal calprotectin. Patients had
to be unresponsive or previously display unacceptable side
effects with glucocorticoid therapy, immunosuppressive
agents, or TNF-a inhibitors. Exclusion criteria encompass
patients with severe disease complications such as stoma,
extensive small-bowel or colon resections, strictures, abdominal abscesses, cancer and tuberculosis. Patients were
screened using physical exams, neurologic exams and questionnaires, including one to classify symptoms of PML as well
as the Inflammatory Bowel Disease Questionnaire.is
The trial investigated both induction and maintenance treatment using vedolizumab. For the induction component, patients were randomized to receive placebo or vedolizumab
300 mg at weeks 0 and 2 and were assessed for disease
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status through week 6. A second open-label cohort received
the same regimen of vedolizumab as the previously
mentioned group receiving induction therapy. This group of
patients was included in the study to meet sample size requirements for the maintenance phase of the trial. Patients
eligible for the maintenance phase of the study were patients
from both cohorts who displayed a clinical response to vedolizumab at week 6. Participants were randomized in a
1:1:1 fashion to vedolizumab dosed every four weeks, every
eight weeks or placebo (frequency not specified) for
52 weeks. Patients who did not achieve a clinical response to
vedolizumab by week 6 of induction therapy continued to
receive vedolizumab 300 mg every four weeks for 52 weeks.
Patients in the placebo group during the induction phase
remained in the placebo group for the maintenance phase.is
Primary end points for the induction trial were clinical remission defined by a CDAI less than or equal to 150 and a
CDAI-100 response, defined as a 100 point CDAI score reduction. The secondary end point was the change in C-reactive
protein from baseline to 6 weeks. Statistical significance for
the entire trial was set at 5 percent (alpha=0.05). Results
showed 14.5 percent of patients receiving vedolizumab and
6.8 percent of patients receiving placebo reached clinical
remission by week 6 (p=0.02). Of those receiving vedolizumab and placebo, 31.4 percent and 25.7 percent, respectively, had a CDAI-100 response (p=0.23). Changes in
C-reactive protein were similar across both groups.JS
The primary end point for the maintenance trial was clinical
remission at week 52 and the secondary end points were
CDAI-100 response at week 52, remission at week 52 without the use of glucocorticoids, and clinical remission at
greater than or equal to 80 percent of all study visits including the final visit at week 52. Results showed 36.4 percent of
patients receiving vedolizumab every four weeks and 39 percent of patients receiving vedolizumab every eight weeks
were in clinical remission at week 52. Only 21.6 percent of
patients in the placebo group reached clinical remission, producing comparison p-values of p=0.004 and p<0.001 for the
four-week and eight-week vedolizumab groups compared to
placebo, respectively. Vedolizumab groups also showed a
trend towards greater proportions of patients with a CDAI100 response and glucocorticoid-free remission than with
placebo; however, the differences in clinical remission were
not significant.ls
This trial displayed moderate effects on induction and maintenance of clinical remission in patients with moderate to
severe Crohn's disease who received vedolizumab therapy.
Patients enrolled in the study had refractory disease and approximately 50 percent of patients had prior treatment failure to other medications, including TNF-a inhibitors. Further
trials are necessary to determine which patients may benefit
most from vedolizumab therapy. Once it comes to market,
vedolizumab will likely be a safer choice than natalizumab
for Crohn's disease due to a lower incidence of PML.lS
On Dec. 9, 2013, a joint meeting of the FDA's Gastrointestinal
Drugs Advisory Committee and the Drug Safety and Risk
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Management Advisory Committee recommended vedolizumab for use in Crohn's disease as well as ulcerative colitis.
Specific recommendations for vedolizumab therapy in
Crohn's disease included use in patients who failed TNF-a
inhibitors or conventional therapy to reduce signs and
symptoms, to achieve clinical remission or glucocorticoidfree remission and to stimulate mucosa! healing in moderate
to severe Crohn's disease. The committee reached unanimous agreement that Takeda Pharmaceuticals appropriately
characterized the low risk of PML with vedolizumab therapy
to support approval.16 Although the committee has shown
support, vedolizumab still needs FDA approval. The FDA has
set a Prescription Drug User Fee Act (PDUFA) Priority Review action date for the indication ofvedolizumab in ulcerative colitis as May 20, 2014. This date is a target for the FDA
to make a final decision on approval. A PDUFA standard review action date for indication in Crohn's disease has been
made for June 18, 2014.17 If approved, vedolizumab will enter the market under the brand name Entyvio®.
Nonpharmacologic Treatment
Along with standard pharmacologic treatments, nonpharmacologic treatments have proven beneficial for Crohn's disease
patients. Lifestyle modifications such as dietary changes and
symptomatic or supportive treatment are important. Maintaining a well-balanced diet promotes healing and relieves
symptoms in many patients suffering from Crohn's disease.
Good nutrition helps compensate for nutritional losses due
to Crohn's disease. Dietary suggestions are different depending on whether the patient is in a period of active or inactive
disease. When the disease state is inactive, patients should
stay hydrated and consume low fiber carbohydrates like legumes, oat bran, and barley, proteins such as lean meats and
eggs, healthy fats like olive oil, fruits, and vegetables. When a
patient's disease is active, health care professionals can recommend applesauce, bananas, bland foods, soft foods, plain
cereals, proteins as accepted, and small, frequent meals. 18
Patients with active disease should also be educated to avoid
high fiber foods, high fat foods, nuts, seeds, popcorn, gluten,
caffeine, alcohol, raw fruits, raw vegetables, dairy, spicy
foods, and larger portions. However, all dietary recommendations remain patient specific. Each patient may also possess his or her own specific trigger food, which should be
avoided, because it may cause flares of symptoms and decreased quality of life. Patients should be advised to keep a
food diary, which should include all foods eaten each day as
well as Crohn's disease symptoms such as abdominal pain, a
description of bowel habits and overall well-being. This
process helps identify triggers, encourages patients to eat
well-balanced foods and allows positive dietary habits to be
observed. Overall, Crohn's disease manifests differently between individuals; therefore, it is best to individualize each
patient's diet to alleviate symptoms.
Maintaining a healthy diet is important, but there are other
nonpharmacologic therapies that may help reduce flare-ups
and prevent symptoms. First, those suffering with Crohn's
disease should stop smoking as this worsens symptoms and
can decrease responsiveness to certain treatments.19 Also,
stress relief and general health maintenance are beneficial in
July 2014 Volume 5, Issue 3
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providing symptomatic relief and preventing exacerbations.
Options for stress relief include relaxation, breathing exercises, meditation, acupuncture, reading books and other relaxing activities. 20 Implementing low-intensity exercise for
30 minutes three times per week aids in diminishing depression, which often accompanies Crohn's disease.21
Numerous other complementary alternative medicines are
available. These are believed to be safe, but may require additional studies to elucidate efficacy in the treatment of
Crohn's disease. These options include probiotics, fecal microbiota transplantation and fish oils. Probiotics are living
microbial food ingredients, which beneficially alter the intestinal flora in an unknown mechanism. Although studies regarding probiotics in Crohn's disease have resulted in mixed
conclusions on efficacy, the use of VSL#3 specifically may
help patients achieve remission. VSL#3 is a mixture of eight
different strands of bacteria, which influence the immune
response by several mechanisms.23 Fecal microbiota transplantation represents an alternative therapy to use when
standard treatments have failed. This process involves transferring a safe, donated stool into the patient via an enema or
nasogastric tube in order to replenish and balance bacteria in
the colon.z4 Fish oils and omega-3 fatty acids may have positive anti-inflammatory effects in the intestines.22 Even though
all of these options are still under investigation, they may be
good options for the treatment of Crohn's disease.
After medications and nonpharmacologic treatments fail as
treatment for Crohn's disease, surgery is the final option.
According to the National Cooperative Crohn's Disease Study,
the probability of requiring surgery is 78 percent after
20 years of Crohn's disease symptoms, and the probability
jumps to 90 percent after 30 years of symptoms.zs Possible
procedures include strictureplasty, resection, colectomy, removal of abscesses (pus-filled sacs) and correction of abnormal tracts or fistulas.26 However, surgery is not curative and
is a last-ditch effort for treating Crohn's disease.
The Pharmacist's Role
As health care providers, pharmacists must be educated in
Crohn's disease pharmacologic and nonpharmacologic
treatments as well as appropriate patient counseling and
recommendation points. Pharmacists should highlight the
importance of avoiding non-steroidal anti-inflammatory
drugs (NSAIDs) such as ibuprofen and naproxen due to
bleeding risk. Within one week of therapy with NSAIDs, approximately 25 percent of patients have flares.19 Many
Crohn's disease patients experience deficiencies in folate and
vitamin 812. Vitamin 812 deficiency is especially prevalent
when the ileum is affected since this is the primary site of
absorption of vitamin 812. Therefore, pharmacists should
recommend frequent screenings and supplementation. Since
sulfasalazine and methotrexate impair folate metabolism,
patients taking these medications require more folic acid
than patients not on these therapies.27 Vitamin D and calcium
may also be depleted in Crohn's disease patients due to
impaired absorption putting patients at increased risk for
osteoporosis.zs Vitamins and supplements should be taken
during both the active and inactive phases of the disease to
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replenish deficiencies.22 Another counseling point to emphasize is the necessity for periodic colonoscopies in which the
frequency is determined by disease severity, duration and
personal or family history of colorectal cancer. The risk of
acquiring colorectal cancer significantly increases eight to 10
years after development of Crohn's disease, and at that point,
patients may require regular colonoscopies every one to two
years.29 It is important to ensure that patients keep a list of
any supplements, over-the-counter or prescription medications they take in order to keep their doctors, pharmacists
and other health care professionals informed. Pharmacists
should also counsel patients on nonpharmacologic treatments, including foods and drinks to avoid and those that
may be better options. As the most accessible health care
provider, it is important for pharmacists to remain knowledgeable and up-to-date on new treatments, recommendations and counseling points to benefit patients suffering from
Crohn's disease.
Conclusion
Crohn's disease patients may feel overwhelmed or burdened
by their disease state and the complexity of their medication
regimens. When experiencing a disease flare, the quality of
life of a Crohn's disease patient is negatively affected. Pharmacists play a large role in helping these patients to better
manage their medications and can provide great insight into
the various pharmacologic and nonpharmacologic therapies
available for treatment of Crohn's disease.
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